AR and adenocarcinoma: Similar to the UW and SU2C mCRPC cohorts, transcriptome analysis revealed that AR-active adenocarcinoma PDX models had negligible MET and RET transcript expression, whereas 3 of 4 SCNPC PDX models and the NCI-H660 cell line had robust MET and RET expression (Fig 2A).